LAS VEGAS--(BW HealthWire)--March 24, 1999--Steroidogenesis
Inhibitors International (OTCBB:STGI) today announced new dates for
the Company's television appearances on three cable TV networks
including CNBC which will feature STGI's cortisol/anti-cortisol
approach to treating diseases, some of them with no known treatment at
the present.

     Orginally scheduled for March 27, Michael Jackson's interview
with STGI's President, Dr. Alfred T. Sapse and Executive Vice
President, Dr. Janet Greeson, on "Investing in America," a sponsored
program, will instead air on April 10 at 2:00PM EST in the United
States. On or about April 25 the same program will be aired in Europe
with a German voice-over translation intended primarily for
German-speaking populations in Switzerland, Germany and Austria.

     The show will present, for the first time to a lay audience in
United States and Europe, the essence of the Cortisol/Anticortisol
Concept developed by Dr. Sapse in 1984. This concept was presented
previously only to medical researchers at the World Congresses and
Symposiums in Berlin, Amsterdam, Tokyo and more recently in Paris,
Vancouver and Las Vegas.

     Viewers of this TV program will learn the role played by
Cortisol, the powerful hormone manufactured by the adrenal gland, in
causing disease or major symptoms of diseases and the potential
therapeutic role of the anticortisol drugs. Dr. Sapse will discuss
STGI's anticortisol drug ANTICORT(TM) as the forerunner of a new class
of drugs intended to enhance the effectiveness of presently used
medications treating AIDS, heart attacks, ulcers, hypertension,
diabetes and psoriasis as well as its own potential effectiveness in
alleviating or reducing symptoms due to cortisol in disorders such as
cancers, multiple sclerosis (MS), Lou Gehrig's disease (ALS), aging
and Alzheimer's; diseases where there is no effective treatment at the
present time.

     STGI is a pharmaceutical R&D Corporation engaged in the
development of anti-cortisol drugs to be used in diseases/conditions
associated with elevated levels of the immunosuppressive hormone
cortisol. STGI's flagship anti-cortisol drug ANTICORT has been
approved by the FDA to be clinically tested in an HIV+ population -- a
condition often associated with "high cortisol", which apparently
plays a major role in the destruction of the immune system as
encountered in HIV+ and AIDS.

     This release may include "forward-looking statement" within the
meaning of section 27A of the Securities Act of 1933 and Section 21E
of the Securities Act of 1034. Although the Company believes that the
expectations reflected in such forward-looking statements are
reasonable it can give no assurance that such expectations will prove
correct. This is neither an offer to buy or sell a security. For
informational purposes only, from sources deemed to be reliable. For
more information visit our World Wide Web page at www.anticort.com.

     CONTACT: STEROIDOGENESIS           PERFORMANCE STRATEGIES
              Janet Greeson, Ph.D.      Richard L. Brown/Chuck Jordan
              (702) 735-7001            (303) 471-5943

              H.L. LANZET INC.
              Herbert Lanzet/DeeDee Lanzet
              (212) 687-0061